Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ONCY

Oncolytics Biotech, Inc.

Dec 06 • 04:00PM ET

1.37

Dollar change -0.03
Percentage change -2.14	%

Healthcare • Biotechnology • Canada • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.37	Insider Own	1.17%	Shs Outstand	73.40M	Perf Week	-7.43%
Market Cap	100.56M	Forward P/E	-	EPS next Y	-0.37	Insider Trans	0.00%	Shs Float	72.54M	Perf Month	-15.95%
Income	-24.00M	PEG	-	EPS next Q	-0.11	Inst Own	8.56%	Short Float / Ratio	2.05% / 3.67	Perf Quarter	-39.38%
Sales	0.00M	P/S	-	EPS this Y	-8.85%	Inst Trans	32.54%	Short Interest	1.49M	Perf Half Y	-13.84%
Book/sh	0.29	P/B	4.69	EPS next Y	-8.92%	ROA	-76.87%	Target Price	5.12	Perf Year	-29.02%
Cash/sh	0.40	P/C	3.40	EPS next 5Y	-	ROE	-113.93%	52W Range	1.09 - 3.39	Perf YTD	-15.95%
Dividend	-	P/FCF	-	EPS past 5Y	17.85%	ROI	-110.59%	52W High	-59.64%	Beta	2.00
Dividend %	-	Quick Ratio	4.53	Sales past 5Y	0.00%	Gross Margin	-	52W Low	25.69%	ATR	0.10
Employees	29	Current Ratio	4.53	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	37.91	Volatility	3.59% 7.17%
Optionable	No	Debt/Eq	0.02	EPS Q/Q	-83.39%	Profit Margin	-	Rel Volume	0.67	Prev Close	1.40
Shortable	Yes	LT Debt/Eq	0.01	Earnings	Nov 03 BMO	Payout	-	Avg Volume	405.38K	Price	1.37
Recom	1.00	SMA20	-7.96%	SMA50	-19.39%	SMA200	-26.63%	Volume	271,281	Change	-2.14%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-06-22	Initiated	Maxim Group	Buy	$3
Feb-17-21	Initiated	H.C. Wainwright	Buy	$15

Nov-29-23 10:45AM	Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment (PR Newswire)
Nov-09-23 08:45AM	Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance (PR Newswire) -15.92%
07:00AM	Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy (PR Newswire)
06:30AM	Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep (PR Newswire)
Nov-05-23 02:29PM	Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2023 Earnings Call Transcript (Insider Monkey)
12:03PM	Loading…
Nov-03-23 12:03PM	Oncolytics Biotech and SOLTI Present Further Positive Pelareorep Translational Data at SITC (PR Newswire)
07:00AM	Oncolytics Biotech Reports Third Quarter 2023 Financial Results and Operational Highlights (PR Newswire)
Oct-23-23 09:50AM	Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise (PR Newswire) +9.03%
08:45AM	Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing (PR Newswire)
07:05AM	Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO (PR Newswire)
07:00AM	Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study (PR Newswire)
Oct-20-23 10:31AM	Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research (PR Newswire)
07:00AM	Oncolytics Biotech to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights (PR Newswire)
Oct-16-23 07:00AM	Oncolytics Biotech To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023 (PR Newswire)
Oct-13-23 09:00AM	New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review (PR Newswire)
09:00AM	Loading…
Oct-11-23 09:00AM	Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment (PR Newswire)
Sep-26-23 08:00AM	THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS (PR Newswire)
Sep-19-23 07:00AM	Oncolytics Biotech® Announces Fireside Chat at the Cantor Global Healthcare Conference (PR Newswire)
Sep-07-23 09:22AM	Oncolytics Biotech® Announces Full Exercise of Over-Allotment Option from Public Offering (PR Newswire) -5.83%
Sep-06-23 07:00AM	Oncolytics Biotech® to Participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-21-23 07:00AM	3 Under-$20 Stocks to Buy for Explosive Returns (InvestorPlace)
Aug-17-23 09:35AM	After Plunging -29.54% in 4 Weeks, Here's Why the Trend Might Reverse for Oncolytics Biotech Inc. (ONCY) (Zacks)
Aug-14-23 07:00AM	Oncolytics Biotech® Reports Second Quarter 2023 Financial Results and Operational Highlights (PR Newswire)
Aug-08-23 08:50AM	Oncolytics Biotech® Successfully Raises US$15 Million to Advance Breast and Pancreatic Cancer Clinical Programs (PR Newswire)
Aug-04-23 07:05AM	Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 43rd Annual Growth Conference (PR Newswire)
07:00AM	Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights (PR Newswire)
Jul-31-23 06:55AM	Oncolytics Biotech® Announces US$15 Million Bought Deal Offering of Units (PR Newswire) -10.32%
Jun-22-23 07:00AM	Oncolytics Biotech's® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial (PR Newswire) +16.67%
Jun-05-23 07:00AM	Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate (PR Newswire)
May-26-23 11:30AM	Oncolytics Biotech® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual Meeting (PR Newswire) -18.98%
05:41PM	Loading…
May-25-23 05:41PM	Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives 50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract (PR Newswire)
May-24-23 10:26AM	CANADA STOCKS-TSX tumbles as bank earnings, US debt deal uncertainty weigh (Reuters) +20.11%
May-10-23 07:00AM	Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders (PR Newswire)
May-07-23 01:18PM	Oncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-05-23 07:00AM	Oncolytics Biotech® Reports First Quarter 2023 Financial Results and Operational Highlights (PR Newswire) +10.34%
Apr-26-23 10:44AM	Oncolytics Biotech® Announces Upcoming Oral Presentation on Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer at the ASCO Annual Meeting (PR Newswire) +12.39%
Apr-12-23 07:23AM	Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference (PR Newswire)
07:00AM	Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights (PR Newswire)
06:45AM	Oncolytics Biotech® Announces Filing and Mailing of the Management Information Circular in Connection with the Annual General Meeting of Shareholders (PR Newswire)
Mar-28-23 07:00AM	Oncolytics Biotech® to Participate in a Panel Presentation at Cantor Fitzgerald's The Future of Oncology Virtual Symposium (PR Newswire)
Mar-27-23 11:57AM	Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Mar-06-23 09:48AM	Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-03-23 07:00AM	Oncolytics Biotech® Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights (PR Newswire) -5.36%
Feb-21-23 07:00AM	Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights (PR Newswire)
Dec-16-22 09:40AM	Is DICE Therapeutics (DICE) Stock Outpacing Its Medical Peers This Year? (Zacks) +6.56%
Dec-08-22 08:45AM	Oncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium (PR Newswire)
Dec-05-22 12:00PM	What Makes Oncolytics Biotech Inc. (ONCY) a Strong Momentum Stock: Buy Now? (Zacks)
Dec-02-22 10:59AM	Oncolytics (ONCY) Up on Lead Drug Securing 2nd FDA Fast Track Tag (Zacks) -12.74%
09:15AM	Oncolytics Biotech Inc. (ONCY) Hit a 52 Week High, Can the Run Continue? (Zacks)
Dec-01-22 07:32AM	Oncolytics Biotech® Receives FDA Fast Track Designation for the Treatment of Advanced/Metastatic Pancreatic Cancer (PR Newswire) +20.45%
Nov-29-22 09:40AM	Is Olink Holding (OLK) Outperforming Other Medical Stocks This Year? (Zacks) +6.49%
Nov-21-22 09:01AM	Oncolytics Biotech® Announces Presentations at the Upcoming San Antonio Breast Cancer Symposium (PR Newswire)
Nov-18-22 09:55AM	Oncolytics Biotech Inc. (ONCY) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Nov-10-22 09:01AM	Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study's Pancreatic Cancer Cohort (PR Newswire) +10.11%
Nov-07-22 08:03AM	Oncolytics Biotech® Reports Third Quarter 2022 Financial Results and Recent Operational Highlights (PR Newswire) +19.05%
08:01AM	Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting (PR Newswire)
Oct-27-22 07:00AM	Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights (PR Newswire)
Oct-18-22 10:46AM	We're Keeping An Eye On Oncolytics Biotech's (TSE:ONC) Cash Burn Rate (Simply Wall St.)
Sep-07-22 07:00AM	Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors (PR Newswire)
Aug-11-22 07:00AM	Oncolytics Biotech® Reports Second Quarter 2022 Financial Results and Recent Operational Highlights (PR Newswire)
Jul-27-22 07:00AM	Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights (PR Newswire) -6.25%
Jul-11-22 06:19AM	Zacks.com featured highlights include Boot Barn, Canada Goose, Pediatrix Medical Group, Leap Therapeutics and Oncolytics Biotech (Zacks)
Jun-28-22 07:00AM	Oncolytics Biotech® Achieves Success Criteria for Efficacy in the Pancreatic Cancer Cohort of GOBLET (PR Newswire)
Jun-17-22 07:00AM	Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors (PR Newswire) +10.13%
Jun-01-22 12:21PM	IIROC Trading Halt - ONC.WT (PR Newswire)
May-11-22 10:19AM	Will Oncolytics Biotech (TSE:ONC) Spend Its Cash Wisely? (Simply Wall St.) -9.24%
May-10-22 07:00AM	Oncolytics Biotech® to Participate in a Fireside Chat at the 2022 RBC Capital Markets Global Healthcare Conference (PR Newswire) -7.75%
May-05-22 04:01PM	Oncolytics Biotech® Reports First Quarter 2022 Financial Results and Recent Operational Highlights (PR Newswire)
May-04-22 07:00AM	Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep's Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting (PR Newswire) +8.33%
May-02-22 07:00AM	Oncolytics Biotech® and SOLTI Announce Upcoming Poster Presentation at the European Society for Medical Oncology Breast Cancer Meeting (PR Newswire) +5.30%
Apr-28-22 07:00AM	Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights (PR Newswire)
Apr-21-22 07:00AM	Oncolytics Biotech® to Present at the Bloom Burton & Co. Healthcare Investor Conference (PR Newswire)
Apr-14-22 07:00AM	Oncolytics Biotech® Announces Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors in Science Translational Medicine (PR Newswire)
Apr-12-22 07:00AM	Oncolytics Biotech® to Participate in a Fireside Chat at the Canaccord Genuity Horizons in Oncology Virtual Conference (PR Newswire)
Apr-08-22 01:05PM	Oncolytics Biotech® Announces Positive Long-Term Survival Data from Phase 1b Glioblastoma Multiforme Trial at the AACR Annual Meeting (PR Newswire)
01:03PM	Oncolytics Biotech® Presents New Data Demonstrating Durable Clinical Benefit in Relapsed/Refractory Multiple Myeloma Patients at the AACR Annual Meeting (PR Newswire)
Apr-06-22 07:00AM	Oncolytics Biotech® Letter to Shareholders - Update on Recent Progress (PR Newswire)
Mar-31-22 07:00AM	Oncolytics Biotech® Provides Positive Safety Update on the Third-Line Metastatic Colorectal Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial (PR Newswire)

Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ONCY

Oncolytics Biotech, Inc.

Upgrade your FINVIZ experience